 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | BMS-986158 / BMS, trotabresib (BMS-986378) / BMS
Enrollment closed, Enrollment change, Trial completion date: Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer (clinicaltrials.gov) - Mar 21, 2024
P1, N=41, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting | N=66 --> 41 | Trial completion date: Jun 2025 --> Jul 2024
- || trotabresib (BMS-986378) / BMS
Trial completion date, Trial primary completion date, Metastases: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas (clinicaltrials.gov) - Jan 11, 2024
P1, N=139, Active, not recruiting, Sponsor: Celgene
Recruiting --> Active, not recruiting | N=66 --> 41 | Trial completion date: Jun 2025 --> Jul 2024 Trial completion date: Apr 2024 --> Mar 2026 | Trial primary completion date: Oct 2023 --> Mar 2024
- | trotabresib (BMS-986378) / BMS
Trial completion date, Trial primary completion date: CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma (clinicaltrials.gov) - Dec 7, 2023
P1, N=20, Active, not recruiting, Sponsor: Celgene
Trial completion date: Apr 2024 --> Mar 2026 | Trial primary completion date: Oct 2023 --> Mar 2024 Trial completion date: Aug 2023 --> Feb 2024 | Trial primary completion date: Aug 2023 --> Feb 2024
- | trotabresib (BMS-986378) / BMS
New P1 trial, Combination therapy: Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis (clinicaltrials.gov) - Nov 18, 2023
P1, N=34, Not yet recruiting, Sponsor: Northwestern University
- || trotabresib (BMS-986378) / BMS
Phase classification, Trial completion date, Trial primary completion date, Combination therapy: A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Nov 13, 2023
P1, N=194, Active, not recruiting, Sponsor: Celgene
Trial completion date: Aug 2023 --> Feb 2024 | Trial primary completion date: Aug 2023 --> Feb 2024 Phase classification: P1b --> P1 | Trial completion date: Mar 2025 --> May 2026 | Trial primary completion date: Sep 2023 --> May 2024
- | BMS-986158 / BMS, trotabresib (BMS-986378) / BMS
Trial completion date, Trial primary completion date: Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer (clinicaltrials.gov) - Jul 28, 2023
P1, N=66, Recruiting, Sponsor: Dana-Farber Cancer Institute
Phase classification: P1b --> P1 | Trial completion date: Mar 2025 --> May 2026 | Trial primary completion date: Sep 2023 --> May 2024 Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Dec 2023 --> Jun 2024
- trotabresib (BMS-986378) / BMS
Trotabresib (CC-90010) combined with concomitant temozolomide (TMZ) plus radiotherapy (RT) and adjuvant TMZ in patients (pts) with newly diagnosed primary glioblastoma (ndGBM): Updated results from a phase Ib/II study (Santander Auditorium - Hall 9) - Jul 27, 2023 - Abstract #ESMO2023ESMO_149;
P1b
30 mg/day is the recommended phase 2 dose. NE, not estimable; OS, overall survival; PFS, progression-free survival.
- | trotabresib (BMS-986378) / BMS
Trial completion date, Trial primary completion date: CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma (clinicaltrials.gov) - Jun 8, 2023
P1, N=20, Active, not recruiting, Sponsor: Celgene
NE, not estimable; OS, overall survival; PFS, progression-free survival. Trial completion date: Mar 2023 --> Aug 2023 | Trial primary completion date: Mar 2023 --> Aug 2023
- || Review, Journal: BRD4: New Hope in the Battle Against Glioblastoma. (Pubmed Central) - May 8, 2023
In addition, several BRD4 inhibitors have been evaluated for therapeutic purposes as monotherapy or in combination with chemotherapy, radiotherapy, and immune therapies. Here, we provide a critical appraisal of studies evaluating various BRD4 inhibitors and degraders as novel treatment strategies against GBM.
- || trotabresib (BMS-986378) / BMS
Enrollment closed, Combination therapy: A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - May 3, 2023
P1b, N=194, Active, not recruiting, Sponsor: Celgene
Here, we provide a critical appraisal of studies evaluating various BRD4 inhibitors and degraders as novel treatment strategies against GBM. Recruiting --> Active, not recruiting
- || trotabresib (BMS-986378) / BMS
Trial completion date, Trial primary completion date, Metastases: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas (clinicaltrials.gov) - Apr 20, 2023
P1, N=139, Active, not recruiting, Sponsor: Celgene
Recruiting --> Active, not recruiting Trial completion date: Nov 2023 --> Apr 2024 | Trial primary completion date: Apr 2023 --> Oct 2023
- || trotabresib (CC-90010) / BMS
New P1 trial, Metastases: A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jan 10, 2023
P1, N=8, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- | BMS-986158 / BMS, trotabresib (BMS-986378) / BMS
Trial completion date, Trial primary completion date: Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer (clinicaltrials.gov) - Dec 28, 2022
P1, N=66, Recruiting, Sponsor: Dana-Farber Cancer Institute
Trial completion date: Nov 2023 --> Apr 2024 | Trial primary completion date: Apr 2023 --> Oct 2023 Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jul 2023 --> Dec 2023
- | trotabresib (BMS-986378) / BMS
Trial completion date, Trial primary completion date: CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma (clinicaltrials.gov) - Dec 15, 2022
P1, N=20, Active, not recruiting, Sponsor: Celgene
Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jul 2023 --> Dec 2023 Trial completion date: Sep 2022 --> Mar 2023 | Trial primary completion date: Sep 2022 --> Mar 2023
- || trotabresib (BMS-986378) / BMS
Trial completion date, Trial primary completion date, Metastases: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas (clinicaltrials.gov) - Dec 15, 2022
P1, N=139, Active, not recruiting, Sponsor: Celgene
Trial completion date: Sep 2022 --> Mar 2023 | Trial primary completion date: Sep 2022 --> Mar 2023 Trial completion date: Jun 2023 --> Nov 2023 | Trial primary completion date: Dec 2022 --> Apr 2023
- | trotabresib (CC-90010) / BMS
Journal: Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: a phase I, "windowofopportunity" study. (Pubmed Central) - Dec 2, 2022
P1, P1b
Plasma pharmacokinetics, blood pharmacodynamics, and safety were comparable with previous results for trotabresib in patients with advanced solid tumors. Investigation of adjuvant trotabresib + temozolomide and concomitant trotabresib + temozolomide + radiotherapy in patients with newly diagnosed glioblastoma is ongoing (NCT04324840).
- | trotabresib (CC-90010) / BMS
Journal, Combination therapy: Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma. (Pubmed Central) - Nov 18, 2022
P1b
Trotabresib combined with TMZ in the adjuvant setting and with TMZ+RT in the concomitant setting was safe and well tolerated in patients with ndGBM, with encouraging treatment durations. Trotabresib 30 mg was established as the RP2D in both settings.
- | trotabresib (BMS-986378) / BMS
Trial completion date, Combination therapy: A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Nov 7, 2022
P1b, N=194, Recruiting, Sponsor: Celgene
Trotabresib 30 mg was established as the RP2D in both settings. Trial completion date: Nov 2024 --> Mar 2025
- trotabresib (CC-90010) / BMS
Trotabresib (CC-90010) in combination with concomitant temozolomide plus radiotherapy and adjuvant temozolomide in patients with newly diagnosed glioblastoma: updated results from a phase 1b/2 study (West/Central Hall) - Sep 28, 2022 - Abstract #SNO2022SNO_463;
P1b
Key objectives are to compare progression-free and overall survival, safety, and tolerability. Longer follow-up from part A and the first disclosure of data from part B will be presented.
- | trotabresib (BMS-986378) / BMS
Trial completion date, Metastases: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas (clinicaltrials.gov) - Jul 20, 2022
P1, N=139, Active, not recruiting, Sponsor: Celgene
Longer follow-up from part A and the first disclosure of data from part B will be presented. Trial completion date: Dec 2022 --> Jun 2023
- | trotabresib (BMS-986378) / BMS
Trial completion date, Trial primary completion date: CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma (clinicaltrials.gov) - Jun 14, 2022
P1, N=20, Active, not recruiting, Sponsor: Celgene
Trial completion date: Dec 2022 --> Jun 2023 Trial completion date: Mar 2022 --> Sep 2022 | Trial primary completion date: Mar 2022 --> Sep 2022
- || trotabresib (BMS-986378) / BMS
Enrollment closed, Metastases: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas (clinicaltrials.gov) - May 17, 2022
P1, N=139, Active, not recruiting, Sponsor: Celgene
Trial completion date: Mar 2022 --> Sep 2022 | Trial primary completion date: Mar 2022 --> Sep 2022 Recruiting --> Active, not recruiting
- || trotabresib (BMS-986378) / BMS
Enrollment change, Trial primary completion date, Combination therapy: A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Feb 3, 2022
P1b, N=194, Recruiting, Sponsor: Celgene
Recruiting --> Active, not recruiting N=126 --> 194 | Trial primary completion date: Apr 2023 --> Aug 2023
- | BMS-986158 / BMS, trotabresib (BMS-986378) / BMS
Enrollment change, Trial primary completion date: Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer (clinicaltrials.gov) - Jan 11, 2022
P1, N=66, Recruiting, Sponsor: Dana-Farber Cancer Institute
N=126 --> 194 | Trial primary completion date: Apr 2023 --> Aug 2023 N=34 --> 66 | Trial primary completion date: Jul 2022 --> Jul 2023
- | trotabresib (BMS-986378) / BMS
Phase classification, Trial completion date, Trial primary completion date: CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma (clinicaltrials.gov) - Jan 4, 2022
P1, N=20, Active, not recruiting, Sponsor: Celgene
N=34 --> 66 | Trial primary completion date: Jul 2022 --> Jul 2023 Phase classification: P1/2 --> P1 | Trial completion date: Aug 2021 --> Mar 2022 | Trial primary completion date: Mar 2021 --> Mar 2022
- trotabresib (CC-90010) / BMS
Trotabresib (CC-90010, BMS-986378), a reversible, potent oral bromodomain and extraterminal inhibitor (BETi) in patients with high-grade gliomas: a phase 1 open-label ‘window of opportunity’ study (Ballroom C) - Nov 16, 2021 - Abstract #SNO2021SNO_1011;
P1/2, P1b
Overall, trotabresib showed good tumor tissue penetration, with PD signals of response, and was well tolerated. A study of trotabresib + temozolomide in first-line glioblastoma is ongoing (NCT04324840).
- trotabresib (CC-90010) / BMS
Adjuvant trotabresib, a reversible potent bromodomain and extraterminal inhibitor, plus temozolomide in patients with newly diagnosed glioblastoma: interim results from a phase 1B dose-finding study (Exhibit Hall D) - Nov 16, 2021 - Abstract #SNO2021SNO_377;
P1b
Adjuvant trotabresib + temozolomide appears well tolerated, with promising preliminary efficacy. Treatment was ongoing at data cutoff in 9 patients in the adjuvant cohort; enrollment is continuing in the adjuvant and concomitant therapy dose-escalation cohorts.
- lenalidomide / Generic mfg.
Super-Enhancer Driven Regulation of CKS1B in Multiple Myeloma: Implications in Mediating Response to BET Inhibitor and Celmod Agent Combination (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_4298;
Translational studies suggest a profound downregulation of CKS1B and key pro-survival effector proteins following combination treatment with BRD4inh and IMiD agents/novel CELMoD agents resulting in synergistic anti-tumor effects. These data provide rationale for testing these agents in the clinic for high-risk and IMiD-relapsed patients.
- || BMS-986158 / BMS, trotabresib (CC-90010) / BMS
Clinical, Review, Journal: Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE. (Pubmed Central) - Sep 30, 2021
This meeting emphasised the value of a coordinated and integrated strategy to drug development in paediatric oncology. A multi-stakeholder approach with multiple companies developing a consensus with academic investigators early in the development of a class of compounds, and then engaging regulatory agencies would improve efficiency, productivity, conserve resources and maximise potential benefit for children with cancer.
- || trotabresib (BMS-986378) / BMS
Trial completion date, Trial primary completion date, Metastases: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas (clinicaltrials.gov) - Aug 18, 2021
P1, N=139, Recruiting, Sponsor: Celgene
A multi-stakeholder approach with multiple companies developing a consensus with academic investigators early in the development of a class of compounds, and then engaging regulatory agencies would improve efficiency, productivity, conserve resources and maximise potential benefit for children with cancer. Trial completion date: Aug 2023 --> Sep 2022 | Trial primary completion date: Aug 2021 --> Sep 2022
- | trotabresib (BMS-986378) / BMS
Enrollment closed: CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma (clinicaltrials.gov) - Mar 26, 2021
P1/2, N=20, Active, not recruiting, Sponsor: Celgene
Trial completion date: Aug 2023 --> Sep 2022 | Trial primary completion date: Aug 2021 --> Sep 2022 Recruiting --> Active, not recruiting
- || Clinical, Review, Journal: Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials. (Pubmed Central) - Feb 13, 2021
All BET inhibitors reviewed in our study exhibited exposure-dependent thrombocytopenia, which may limit their clinical application. Moreover, further efforts are necessary to explore the optimal dosing schemes and combinations to maximize the efficacy of BET inhibitors.
- CC-90010 / BMS
[VIRTUAL] CC-90010, a Reversible, Potent Oral Bromodomain and Extraterminal Inhibitor (BETi) in Patients (pts) with Advanced Solid Tumors (aSTs) and Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Longer Follow-Up From Parts A & B and First Reporting of Part C of a Phase 1 Study (Channel 1) - Feb 8, 2021 - Abstract #TAT2021TAT_195;
P1
CCR1 modulation was similar in A and B after first and last dose at the RP2D. Conclusions Overall, CC-90010 was very well tolerated with promising antitumor activity and PK not impacted by food intake, supporting exploration in combination therapy.
- || trotabresib (CC-90010) / BMS
Clinical, P1 data, Journal: Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma. (Pubmed Central) - Jan 21, 2021
P1
Conclusions Overall, CC-90010 was very well tolerated with promising antitumor activity and PK not impacted by food intake, supporting exploration in combination therapy. CC-90010 is well-tolerated, with single-agent activity in patients with heavily pretreated, advanced solid tumors.
- ||| trotabresib (BMS-986378) / BMS
Enrollment change: CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma (clinicaltrials.gov) - Jan 8, 2021
P1/2, N=25, Recruiting, Sponsor: Celgene
CC-90010 is well-tolerated, with single-agent activity in patients with heavily pretreated, advanced solid tumors. N=10 --> 25
- ||||| CC-90010 / BMS
After 10 years of the discovery of BET bromodomain inhibitors we continue to have new compounds as CC-90010 with CNS activity @VicMorenoGarcia @myESMO #ESMO2020 @OncoAlert @OncoReporte (Twitter) - Sep 20, 2020
- trotabresib (BMS-986378) / BMS
Enrollment open, Phase classification, Trial completion date, Trial initiation date, Trial primary completion date: CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma (clinicaltrials.gov) - Jul 23, 2020
P1/2, N=10, Recruiting, Sponsor: Celgene
N=10 --> 25 Not yet recruiting --> Recruiting | Phase classification: P1 --> P1/2 | Trial completion date: Jan 2022 --> Aug 2021 | Initiation date: Aug 2019 --> Jan 2020 | Trial primary completion date: Dec 2021 --> Mar 2021
- ||| trotabresib (BMS-986378) / BMS
Enrollment open, Combination therapy: A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Jul 22, 2020
P1b, N=126, Recruiting, Sponsor: Celgene
Not yet recruiting --> Recruiting | Phase classification: P1 --> P1/2 | Trial completion date: Jan 2022 --> Aug 2021 | Initiation date: Aug 2019 --> Jan 2020 | Trial primary completion date: Dec 2021 --> Mar 2021 Not yet recruiting --> Recruiting
- CC-90010 / BMS
[VIRTUAL] CC-90010, a reversible, oral bromodomain and extra-terminal (BET) inhibitor in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory (R/R) non-Hodgkin lymphoma: Updated results of a phase I study (Channel 3) - Jul 21, 2020 - Abstract #ESMO2020ESMO_1235;
P1
Funding: Celgene Corporation. Clinical trial identification: Study ID: CC-90010-ST-001 NCT03220347; 2015-004371-79 (EudraCT Number).
- || trotabresib (BMS-986378) / BMS
Enrollment change, Combination therapy: A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Apr 29, 2020
P1b, N=126, Not yet recruiting, Sponsor: Celgene
Clinical trial identification: Study ID: CC-90010-ST-001 NCT03220347; 2015-004371-79 (EudraCT Number). N=96 --> 126
- ||| trotabresib (BMS-986378) / BMS
New P1 trial, Combination therapy: A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Mar 26, 2020
P1b, N=96, Not yet recruiting, Sponsor: Celgene
- CC-90010 / BMS
Phase I study of CC-90010, a reversible, oral BET inhibitor in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL) (Amphitheatre Bordeaux) - Feb 7, 2020 - Abstract #TAT2020TAT_89;
P1
The safety profile, long t1/2, and sufficient target engagement enabled less frequent dosing. These data provide the rationale for further exploration of CC-90010 alone and in combination with other agents.
- CC-90010 / Celgene
Phase I study of CC-90010 in patients with advanced solid tumours and relapsed/refractory non-Hodgkin lymphoma (R/R NHL) (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_1844;
P1
CC-90010 had a long terminal half-life that enabled less frequent dosing and promising anticancer activity. Dose escalation is complete, and expansion in select advanced malignancies is ongoing.
- | trotabresib (BMS-986378) / BMS
New P1 trial: CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma (clinicaltrials.gov) - Aug 5, 2019
P1, N=10, Not yet recruiting, Sponsor: Celgene
- | BMS-986158 / BMS, trotabresib (BMS-986378) / BMS
Enrollment open: Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer (clinicaltrials.gov) - Jul 7, 2019
P1, N=34, Recruiting, Sponsor: Dana-Farber Cancer Institute
Dose escalation is complete, and expansion in select advanced malignancies is ongoing. Not yet recruiting --> Recruiting
- | BMS-986158 / BMS, trotabresib (BMS-986378) / BMS
New P1 trial: Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer (clinicaltrials.gov) - May 2, 2019
P1, N=34, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
- || trotabresib (BMS-986378) / BMS
Trial completion date, Trial primary completion date, Metastases: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas (clinicaltrials.gov) - Apr 8, 2019
P1, N=145, Recruiting, Sponsor: Celgene
Not yet recruiting --> Recruiting Trial completion date: Apr 2022 --> Aug 2023 | Trial primary completion date: May 2020 --> Aug 2021
- ||| trotabresib (BMS-986378) / BMS
Enrollment open, Metastases: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas (clinicaltrials.gov) - Sep 12, 2017
P1, N=115, Recruiting, Sponsor: Celgene
Trial completion date: Apr 2022 --> Aug 2023 | Trial primary completion date: May 2020 --> Aug 2021 Not yet recruiting --> Recruiting
- ||| trotabresib (BMS-986378) / BMS
New P1 trial, Metastases: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas (clinicaltrials.gov) - Jul 18, 2017
P1, N=100, Not yet recruiting, Sponsor: Celgene